CO6382170A2 - Composiciones farmacéuticas que comprenden 3-(1.h.-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]pirrol-2,5-diona o una sal farmacéuticamente aceptable del mismo y procesos para su producción. - Google Patents

Composiciones farmacéuticas que comprenden 3-(1.h.-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]pirrol-2,5-diona o una sal farmacéuticamente aceptable del mismo y procesos para su producción.

Info

Publication number
CO6382170A2
CO6382170A2 CO10088697A CO10088697A CO6382170A2 CO 6382170 A2 CO6382170 A2 CO 6382170A2 CO 10088697 A CO10088697 A CO 10088697A CO 10088697 A CO10088697 A CO 10088697A CO 6382170 A2 CO6382170 A2 CO 6382170A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
production
pirrol
diona
quinazolin
Prior art date
Application number
CO10088697A
Other languages
English (en)
Inventor
Charu Kochhar
Unmesh Deodhar
Aravid Kerudi
G V Babu
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39495348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6382170(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of CO6382170A2 publication Critical patent/CO6382170A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)

Abstract

La solicitud se refiere a composiciones farmacéuticas sólidas adecuadas para administración oral, las cuales comprenden un derivado de indolil-maleimida, a un procedimiento para su producción, y al uso de las composiciones farmacéuticas.
CO10088697A 2007-12-21 2010-07-21 Composiciones farmacéuticas que comprenden 3-(1.h.-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]pirrol-2,5-diona o una sal farmacéuticamente aceptable del mismo y procesos para su producción. CO6382170A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07150347 2007-12-21

Publications (1)

Publication Number Publication Date
CO6382170A2 true CO6382170A2 (es) 2012-02-15

Family

ID=39495348

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10088697A CO6382170A2 (es) 2007-12-21 2010-07-21 Composiciones farmacéuticas que comprenden 3-(1.h.-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]pirrol-2,5-diona o una sal farmacéuticamente aceptable del mismo y procesos para su producción.

Country Status (21)

Country Link
US (1) US20100316713A1 (es)
EP (1) EP2240164A2 (es)
JP (2) JP5525453B2 (es)
KR (1) KR20100103625A (es)
CN (1) CN101883558A (es)
AR (1) AR069799A1 (es)
AU (1) AU2008340019B2 (es)
BR (1) BRPI0820839A2 (es)
CA (1) CA2709909A1 (es)
CL (1) CL2008003823A1 (es)
CO (1) CO6382170A2 (es)
EC (1) ECSP10010360A (es)
IL (1) IL205931A0 (es)
MA (1) MA31950B1 (es)
MY (1) MY158293A (es)
NZ (1) NZ586313A (es)
PE (1) PE20091522A1 (es)
RU (1) RU2485951C2 (es)
TN (1) TN2010000243A1 (es)
TW (1) TWI449541B (es)
WO (1) WO2009080762A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069799A1 (es) * 2007-12-21 2010-02-17 Novartis Ag Composicion farmaceutica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403754B (en) * 1995-11-20 2000-09-01 Lilly Co Eli Protein kinase c inhibitor
TWI324064B (en) * 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
KR20080021634A (ko) * 2005-06-02 2008-03-07 쉐링 코포레이션 약제학적 조성물 및 이를 사용한 치료 방법
AU2006272760A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US7762932B2 (en) * 2007-09-17 2010-07-27 Fitness Anywhere, Inc. Inelastic exercise device having a limited range
AR069799A1 (es) * 2007-12-21 2010-02-17 Novartis Ag Composicion farmaceutica

Also Published As

Publication number Publication date
AU2008340019B2 (en) 2012-05-03
US20100316713A1 (en) 2010-12-16
TWI449541B (zh) 2014-08-21
WO2009080762A2 (en) 2009-07-02
TN2010000243A1 (en) 2011-11-11
TW200940106A (en) 2009-10-01
EP2240164A2 (en) 2010-10-20
JP2014040477A (ja) 2014-03-06
WO2009080762A3 (en) 2009-09-11
RU2010129544A (ru) 2012-01-27
JP2011506576A (ja) 2011-03-03
KR20100103625A (ko) 2010-09-27
JP5525453B2 (ja) 2014-06-18
BRPI0820839A2 (pt) 2015-06-16
ECSP10010360A (es) 2010-08-31
CL2008003823A1 (es) 2010-01-22
AR069799A1 (es) 2010-02-17
PE20091522A1 (es) 2009-10-29
MA31950B1 (fr) 2010-12-01
CA2709909A1 (en) 2009-07-02
NZ586313A (en) 2012-08-31
IL205931A0 (en) 2010-11-30
MY158293A (en) 2016-09-30
AU2008340019A1 (en) 2009-07-02
CN101883558A (zh) 2010-11-10
RU2485951C2 (ru) 2013-06-27

Similar Documents

Publication Publication Date Title
AR078846A1 (es) Composicion para el tratamiento de la enfermedad de alzheimer
DOP2006000170A (es) Nuevos derivados de espirocromanona
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
NO20084752L (no) Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disse
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
AR050717A1 (es) Composiciones farmaceuticas
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
AR058780A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
NO20084850L (no) MGLUR5 modulatorer I
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
AR062397A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis
WO2008006795A3 (en) Indole compounds
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
NO20044547L (no) Nye farmasoytiske sammensetninger inneholdende flibanserin
ME00979B (me) DERIVATI INDOL-2-ONA, DISUPSTITUISANI NA 3-POZICIJI, NJIHOVO DOBIJANJE l PRIMJENA U TERAPIJI
UY29445A1 (es) Composiciones para la transmisión transmucosa oral de la metformina
ECSP088647A (es) Nueva sal de citrato de un derivado de indol y su uso farmacéutico

Legal Events

Date Code Title Description
FC Application refused